These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 9126152)

  • 1. Gene therapy for Parkinson's disease: an approach to the prevention or palliation of levodopa-associated motor complications.
    Mouradian MM; Chase TN
    Exp Neurol; 1997 Mar; 144(1):51-7. PubMed ID: 9126152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
    During MJ; Kaplitt MG; Stern MB; Eidelberg D
    Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications.
    Chase TN; Oh JD
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S122-9; discussion S129-30. PubMed ID: 10762139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease.
    Olanow CW; Obeso JA; Stocchi F
    Nat Clin Pract Neurol; 2006 Jul; 2(7):382-92. PubMed ID: 16932589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors.
    Carlsson T; Winkler C; Burger C; Muzyczka N; Mandel RJ; Cenci A; Björklund A; Kirik D
    Brain; 2005 Mar; 128(Pt 3):559-69. PubMed ID: 15659429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson's disease.
    Chase TN; Engber TM; Mouradian MM
    Neurology; 1994 Jul; 44(7 Suppl 6):S15-8. PubMed ID: 7519334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The therapeutic concept of continuous dopaminergic stimulation (CDS) in the treatment of Parkinson's disease.
    Stocchi F
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S68-71. PubMed ID: 20083012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease.
    Mouradian MM; Heuser IJ; Baronti F; Chase TN
    Ann Neurol; 1990 Jan; 27(1):18-23. PubMed ID: 2301923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments.
    Encarnacion EV; Hauser RA
    Eur Neurol; 2008; 60(2):57-66. PubMed ID: 18480609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preventing levodopa-induced dyskinesias.
    Olanow CW; Obeso JA
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S167-76; discussion S176-8. PubMed ID: 10762145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment.
    Thanvi B; Lo N; Robinson T
    Postgrad Med J; 2007 Jun; 83(980):384-8. PubMed ID: 17551069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levodopa/dopamine replacement strategies in Parkinson's disease--future directions.
    Olanow CW
    Mov Disord; 2008; 23 Suppl 3():S613-22. PubMed ID: 18781663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease.
    Chase TN
    Drugs; 1998; 55 Suppl 1():1-9. PubMed ID: 9483164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glutamate-mediated striatal dysregulation and the pathogenesis of motor response complications in Parkinson's disease.
    Oh JD; Chase TN
    Amino Acids; 2002; 23(1-3):133-9. PubMed ID: 12373527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia.
    Jarraya B; Boulet S; Ralph GS; Jan C; Bonvento G; Azzouz M; Miskin JE; Shin M; Delzescaux T; Drouot X; Hérard AS; Day DM; Brouillet E; Kingsman SM; Hantraye P; Mitrophanous KA; Mazarakis ND; Palfi S
    Sci Transl Med; 2009 Oct; 1(2):2ra4. PubMed ID: 20368163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Motor complications associated with chronic levodopa therapy in Parkinson's disease.
    Obeso JA; Grandas F; Vaamonde J; Luquin MR; Artieda J; Lera G; Rodriguez ME; Martinez-Lage JM
    Neurology; 1989 Nov; 39(11 Suppl 2):11-9. PubMed ID: 2685647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.
    Kondo T
    J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathophysiology of motor fluctuations in Parkinson's disease.
    Widnell K
    Mov Disord; 2005; 20 Suppl 11():S17-22. PubMed ID: 15822108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.